Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2025.

NewLimit was founded to develop medicines that add healthy years to each human life. Initially, we thought it would take many ...

NewLimit’s Series B raise adds fuel to Silicon Valley’s growing obsession with anti-aging science and biohacking immortality.

NewLimit, a startup that aims to increase how long people can live a healthy life by genetically programming their cells, has ...

Coinbase CEO Brian Armstrong believes this situation can be reversed, and says a health startup he cofounded is making faster ...

Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a ...

NewLimit raises $130M Series B led by Kleiner Perkins to advance epigenetic reprogramming research for liver disease ...